Trial Profile
A Post Marketing Surveillance Study to Monitor the Reactogenicity and Safety of Vaxem Hib When Administered According to the Prescribing Information in Korea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Sep 2012
Price :
$35
*
At a glance
- Drugs TAK 816 (Primary)
- Indications Haemophilus infections
- Focus Adverse reactions
- Sponsors Novartis; Novartis Vaccines
- 10 Sep 2012 Actual patient number changed from 759 to 764, as reported by ClinicalTrials.gov.
- 10 Sep 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.